AHR-12245: a potential anti-absence drug

David N. Johnson, H. Steve White, Ewart A. Swinyard, Timothy E Albertson, Brian F. Kilpatrick

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

AHR-12245, 2-(4-chlorophenyl)-3H-imadazo[4,5-b]pyridine-3-acetamid, ethosuximide, Na valproate, phenytoin, and clonazepam were evaluated in mice and rats with a battery of well-standardized anticonvulsant test procedures. The results obtained indicate that the anticonvulsant profile of AHR-12245 is similar to that for ethosuximide and clonazepam. AHR-12245 is effective in nontoxic intraperitoneal doses in mice by the maximal electroshock seizure (MES), pentylenetatrazol (s.c. PTZ), bicuculline, and picrotoxin tests but ineffective against strychnine-induced seizures; it is effective after nontoxic oral doses in both mice and rats by the s.c. PTZ test and ineffective by the MES test. The candidate antiepileptic substance was also ineffective against seizures induced in amygdala and corneally kindled rats. The PIs for AHR-12245 by the s.c. PTZ test were 4.5 to 12 times higher than those for the prototype agents, except that for clonazepam when administered orally in mice. The in vitro studies indicate that AHR-12245 is a weak inhibitor of benzodiazepine (BDZ) receptor binding but does inhibit adenosine uptake. These results indicate that AHR-12245 is a relatively nontoxic agent with a profile of anticonvulsant action which suggests it should be useful in generalized absence seizures.

Original languageEnglish (US)
Pages (from-to)64-70
Number of pages7
JournalEpilepsy Research
Volume8
Issue number1
DOIs
StatePublished - 1991

Fingerprint

Seizures
Clonazepam
Anticonvulsants
Ethosuximide
Pharmaceutical Preparations
Electroshock
Absence Epilepsy
Strychnine
Picrotoxin
Bicuculline
Valproic Acid
Phenytoin
GABA-A Receptors
Amygdala
Adenosine
2-(4-chlorophenyl)-3H-imidazo(4,5-b)pyridine-3-acetamide

Keywords

  • Anticonvulsant activity
  • Kindled rats
  • Maximal seizures
  • Neurotoxicity
  • Protective indices
  • Threshold seizures

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health
  • Neurology

Cite this

Johnson, D. N., White, H. S., Swinyard, E. A., Albertson, T. E., & Kilpatrick, B. F. (1991). AHR-12245: a potential anti-absence drug. Epilepsy Research, 8(1), 64-70. https://doi.org/10.1016/0920-1211(91)90037-G

AHR-12245 : a potential anti-absence drug. / Johnson, David N.; White, H. Steve; Swinyard, Ewart A.; Albertson, Timothy E; Kilpatrick, Brian F.

In: Epilepsy Research, Vol. 8, No. 1, 1991, p. 64-70.

Research output: Contribution to journalArticle

Johnson, DN, White, HS, Swinyard, EA, Albertson, TE & Kilpatrick, BF 1991, 'AHR-12245: a potential anti-absence drug', Epilepsy Research, vol. 8, no. 1, pp. 64-70. https://doi.org/10.1016/0920-1211(91)90037-G
Johnson, David N. ; White, H. Steve ; Swinyard, Ewart A. ; Albertson, Timothy E ; Kilpatrick, Brian F. / AHR-12245 : a potential anti-absence drug. In: Epilepsy Research. 1991 ; Vol. 8, No. 1. pp. 64-70.
@article{ac31680910474928a7518165fff29da3,
title = "AHR-12245: a potential anti-absence drug",
abstract = "AHR-12245, 2-(4-chlorophenyl)-3H-imadazo[4,5-b]pyridine-3-acetamid, ethosuximide, Na valproate, phenytoin, and clonazepam were evaluated in mice and rats with a battery of well-standardized anticonvulsant test procedures. The results obtained indicate that the anticonvulsant profile of AHR-12245 is similar to that for ethosuximide and clonazepam. AHR-12245 is effective in nontoxic intraperitoneal doses in mice by the maximal electroshock seizure (MES), pentylenetatrazol (s.c. PTZ), bicuculline, and picrotoxin tests but ineffective against strychnine-induced seizures; it is effective after nontoxic oral doses in both mice and rats by the s.c. PTZ test and ineffective by the MES test. The candidate antiepileptic substance was also ineffective against seizures induced in amygdala and corneally kindled rats. The PIs for AHR-12245 by the s.c. PTZ test were 4.5 to 12 times higher than those for the prototype agents, except that for clonazepam when administered orally in mice. The in vitro studies indicate that AHR-12245 is a weak inhibitor of benzodiazepine (BDZ) receptor binding but does inhibit adenosine uptake. These results indicate that AHR-12245 is a relatively nontoxic agent with a profile of anticonvulsant action which suggests it should be useful in generalized absence seizures.",
keywords = "Anticonvulsant activity, Kindled rats, Maximal seizures, Neurotoxicity, Protective indices, Threshold seizures",
author = "Johnson, {David N.} and White, {H. Steve} and Swinyard, {Ewart A.} and Albertson, {Timothy E} and Kilpatrick, {Brian F.}",
year = "1991",
doi = "10.1016/0920-1211(91)90037-G",
language = "English (US)",
volume = "8",
pages = "64--70",
journal = "Epilepsy Research",
issn = "0920-1211",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - AHR-12245

T2 - a potential anti-absence drug

AU - Johnson, David N.

AU - White, H. Steve

AU - Swinyard, Ewart A.

AU - Albertson, Timothy E

AU - Kilpatrick, Brian F.

PY - 1991

Y1 - 1991

N2 - AHR-12245, 2-(4-chlorophenyl)-3H-imadazo[4,5-b]pyridine-3-acetamid, ethosuximide, Na valproate, phenytoin, and clonazepam were evaluated in mice and rats with a battery of well-standardized anticonvulsant test procedures. The results obtained indicate that the anticonvulsant profile of AHR-12245 is similar to that for ethosuximide and clonazepam. AHR-12245 is effective in nontoxic intraperitoneal doses in mice by the maximal electroshock seizure (MES), pentylenetatrazol (s.c. PTZ), bicuculline, and picrotoxin tests but ineffective against strychnine-induced seizures; it is effective after nontoxic oral doses in both mice and rats by the s.c. PTZ test and ineffective by the MES test. The candidate antiepileptic substance was also ineffective against seizures induced in amygdala and corneally kindled rats. The PIs for AHR-12245 by the s.c. PTZ test were 4.5 to 12 times higher than those for the prototype agents, except that for clonazepam when administered orally in mice. The in vitro studies indicate that AHR-12245 is a weak inhibitor of benzodiazepine (BDZ) receptor binding but does inhibit adenosine uptake. These results indicate that AHR-12245 is a relatively nontoxic agent with a profile of anticonvulsant action which suggests it should be useful in generalized absence seizures.

AB - AHR-12245, 2-(4-chlorophenyl)-3H-imadazo[4,5-b]pyridine-3-acetamid, ethosuximide, Na valproate, phenytoin, and clonazepam were evaluated in mice and rats with a battery of well-standardized anticonvulsant test procedures. The results obtained indicate that the anticonvulsant profile of AHR-12245 is similar to that for ethosuximide and clonazepam. AHR-12245 is effective in nontoxic intraperitoneal doses in mice by the maximal electroshock seizure (MES), pentylenetatrazol (s.c. PTZ), bicuculline, and picrotoxin tests but ineffective against strychnine-induced seizures; it is effective after nontoxic oral doses in both mice and rats by the s.c. PTZ test and ineffective by the MES test. The candidate antiepileptic substance was also ineffective against seizures induced in amygdala and corneally kindled rats. The PIs for AHR-12245 by the s.c. PTZ test were 4.5 to 12 times higher than those for the prototype agents, except that for clonazepam when administered orally in mice. The in vitro studies indicate that AHR-12245 is a weak inhibitor of benzodiazepine (BDZ) receptor binding but does inhibit adenosine uptake. These results indicate that AHR-12245 is a relatively nontoxic agent with a profile of anticonvulsant action which suggests it should be useful in generalized absence seizures.

KW - Anticonvulsant activity

KW - Kindled rats

KW - Maximal seizures

KW - Neurotoxicity

KW - Protective indices

KW - Threshold seizures

UR - http://www.scopus.com/inward/record.url?scp=0025810087&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025810087&partnerID=8YFLogxK

U2 - 10.1016/0920-1211(91)90037-G

DO - 10.1016/0920-1211(91)90037-G

M3 - Article

C2 - 1905625

AN - SCOPUS:0025810087

VL - 8

SP - 64

EP - 70

JO - Epilepsy Research

JF - Epilepsy Research

SN - 0920-1211

IS - 1

ER -